西比曼生物：阿斯利康将收购GPC3装甲型CAR-T疗法在中国的剩余权益

Core Viewpoint - The agreement between Westaim Biopharma and AstraZeneca allows AstraZeneca to acquire 50% of Westaim's rights for the development and commercialization of C-CAR031 in China, granting AstraZeneca exclusive global rights for C-CAR031 [1] Group 1 - AstraZeneca will pay Westaim up to $630 million, which includes an upfront payment for the GPC3 project in China as well as milestone payments related to development, regulatory, and sales achievements [1] - AstraZeneca already holds the rights for the development, production, and commercialization of C-CAR031 outside of China, and Westaim remains eligible for additional milestone payments and royalties for global development [1]